Truist Securities Reiterates Buy on Immunovant, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Immunovant (NASDAQ:IMVT) and maintained a price target of $30.
September 26, 2023 | 4:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunovant's stock rating has been reiterated as 'Buy' by Truist Securities with a maintained price target of $30.
The reiteration of a 'Buy' rating by a reputable analyst like Robyn Karnauskas from Truist Securities is a positive signal for Immunovant. The maintained price target of $30 also indicates confidence in the company's performance, which could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100